Executive Summary

A novel class of agents for the treatment of retinal disease demonstrating:

• Statistically significant improvement in LLVA indicating improved retinal function.
• Inhibition of GA lesion expansion.
• No evidence of sustained increase in IOP or cataractogenisis.
• No evidence of refractility.
• Patents granted in over 30 countries for its use in Dry-AMD and GA.